- Irwin Naturals (IWIN) has secured a credit facility with its existing commercial lender for up to $60 million
- Out of that amount, $40 million is currently committed
- This is part of Irwin’s strategy to accelerate its rollup and become a large player in the world of psychedelic mental health clinics
- Irwin Naturals is a nutraceutical formulator leveraging its brand to enter into the cannabis and psychedelic sectors
- Irwin Naturals (IWIN) last traded at $4.30 per share
Irwin Naturals (IWIN) has secured a credit facility with its existing commercial lender for up to $60 million.
Out of that amount, $40 million is currently committed.
The rate of the financing is variable based on credit facility margins.
Half of the facility is in place until August 2024, with a maturity date of February 2028, while half is designed to support day-to-day operations and is in place until February 2028.
This is part of Irwin’s strategy to accelerate its rollup and become a large player in the world of psychedelic mental health clinics.
“This is not just a vote of confidence in our business model, it is an endorsement of management’s ability to execute and continue leading within the mental health care sector,” noted Klee Irwin, CEO of Irwin Naturals.
Irwin Naturals began in a different sector of healthcare in 1994, providing nutraceutical products now sold in over 100,000 storefronts in North America.
The company recently moved into psychedelic mental healthcare, announcing its plan to build a national chain of clinics under the umbrella of Irwin Naturals Emergence.
Irwin Naturals Emergence recently announced its LOI to acquire Braxia Scientific Corp., a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders.
Irwin Naturals has been a nutraceutical formulator since 1994. It is leveraging its household name to enter into the cannabis and psychedelic sectors.
Irwin Naturals (IWIN) opened trading at $4.30.
